3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Conditions
Carcinoma, Renal Cell
23
Kidney Neoplasms
7
Carcinoma, Hepatocellular
7
Osteosarcoma
5
Sarcoma, Ewing
4
Neoplasm Metastasis
4
Sarcoma
3
Clear-cell metastatic renal cell carcinoma
3
Recurrence
2
Prostatic Neoplasms
2
Neuroendocrine Tumors
2
Neoplasms
2
Colorectal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma
2
Adrenocortical Carcinoma
2
von Hippel-Lindau Disease
1
Wilms Tumor
1
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Urachal adenocarcinoma
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Sjogren's Syndrome
1
Scleroderma, Systemic
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Interventions
pembrolizumab
4
Doxorubicin
3
Specimen Handling
2
spartalizumab
1
regorafenib
1
peposertib
1
liposomal doxorubicin
1
cabozantinib
1
X-Rays
1
Standard of Care
1
Quality of Life
1
Propranolol
1
Magnetic Resonance Spectroscopy
1
Injections
1
Ifosfamide
1
Histamine H2 Antagonists
1
Famotidine
1
Dactinomycin
1
Biopsy
1
Angptl4 protein, mouse
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Histiocytoma, Malignant Fibrous
×
cabozantinib
×
Clear all
NCT05182164
2025-10-07
PEMBROCABOSARC
Institut Bergonié
Phase 2
Recruiting
119 enrolled